Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies

NCT01096355 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: gamma-secretase/Notch signalling pathway inhibitor RO4929097
OTHER: diagnostic laboratory biomarker analysis
OTHER: pharmacogenomic studies
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)